Marien Hospital Duesseldorf GmbH
- Address
- lock Available on a paid plan
Hematologic Oncology – Myelodysplastic Syndromes
The department focuses on hemic and lymphatic diseases with a special emphasis on myelodysplastic syndrome, aiming to improve anemia management in patients who require transfusions.
- Evaluation of novel erythropoiesis‑stimulating agents
- Assessment of transfusion independence
- Quality‑of‑life outcomes
This work supports the development of more effective treatments for low‑risk MDS and seeks to reduce the burden of chronic transfusion therapy.
Solid Tumor Immunotherapy Trials
In the area of neoplasms, the site investigates innovative bispecific T‑cell engaging molecules for patients with recurrent or refractory solid cancers.
- Safety and tolerability of TCER® agents
- Combination with checkpoint inhibitors
- Evaluation of anti‑tumor activity
The goal is to expand therapeutic options for solid tumors and harness the immune system to achieve durable responses.
Integrated Oncology & Hematology Research at Marien Hospital Düsseldorf
Marien Hospital Düsseldorf’s oncology and hematology department conducts a limited but impactful portfolio of trials across hemic and lymphatic diseases and neoplasms, addressing both blood‑related disorders and solid cancers.
- Comparative effectiveness of new anemia therapies
- Early clinical evaluation of immune‑engaging molecules
- Multi‑disciplinary investigator collaboration
These studies aim to bring forward safer, more effective treatments and improve patient outcomes across multiple cancer types.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 76 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 74 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Pfizer Inc.3active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Marien Hospital Duesseldorf GmbH
lock Showing 1 of 39 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) | Celgene Corp. | Phase IV | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 76 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 6 | Unknown | 2018-10-18 | 2026-07-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.